Hence, targeting Ras/Raf/MEk/Erk is regarded as a potential approach to treating HCC (36), esophageal carcinoma (48), acute lymphoblastic leukemia (49), and melanoma (50). Here, MAP2K7 is linked to hepatocellular carcinoma.